Unknown

Dataset Information

0

A combination treatment based on drug repurposing demonstrates mutation-agnostic efficacy in pre-clinical retinopathy models.

ABSTRACT: Inherited retinopathies are devastating diseases that in most cases lack treatment options. Disease-modifying therapies that mitigate pathophysiology regardless of the underlying genetic lesion are desirable due to the diversity of mutations found in such diseases. We tested a systems pharmacology-based strategy that suppresses intracellular cAMP and Ca2+ activity via G protein-coupled receptor (GPCR) modulation using tamsulosin, metoprolol, and bromocriptine coadministration. The treatment improves cone photoreceptor function and slows degeneration in Pde6βrd10 and RhoP23H/WT retinitis pigmentosa mice. Cone degeneration is modestly mitigated after a 7-month-long drug infusion in PDE6A-/- dogs. The treatment also improves rod pathway function in an Rpe65-/- mouse model of Leber congenital amaurosis but does not protect from cone degeneration. RNA-sequencing analyses indicate improved metabolic function in drug-treated Rpe65-/- and rd10 mice. Our data show that catecholaminergic GPCR drug combinations that modify second messenger levels via multiple receptor actions provide a potential disease-modifying therapy against retinal degeneration.

SUBMITTER: Leinonen H 

PROVIDER: S-EPMC11251169 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Inherited retinopathies are devastating diseases that in most cases lack treatment options. Disease-modifying therapies that mitigate pathophysiology regardless of the underlying genetic lesion are desirable due to the diversity of mutations found in such diseases. We tested a systems pharmacology-based strategy that suppresses intracellular cAMP and Ca2+ activity via G protein-coupled receptor (GPCR) modulation using tamsulosin, metoprolol, and bromocriptine coadministration. The treatment impr  ...[more]

Similar Datasets

Transcriptomics A combination treatment based on drug repurposing demonstrates mutation agnostic efficacy in pre-clinical retinopathy models.
2024-06-06 | GSE238218 | GEO
Transcriptomics A combination treatment based on drug repurposing demonstrates mutation agnostic efficacy in pre-clinical retinopathy models. [RNA-seq: Rd10]
2024-06-06 | GSE238217 | GEO
Transcriptomics A combination treatment based on drug repurposing demonstrates mutation-agnostic efficacy in pre-clinical retinopathy models [scRNA-seq: Rd10]
2024-06-06 | GSE234797 | GEO
Transcriptomics A combination treatment based on drug repurposing demonstrates mutation-agnostic efficacy in pre-clinical retinopathy models [scRNA-seq: Rpe65-KO]
2024-06-06 | GSE263877 | GEO
Transcriptomics A combination treatment based on drug repurposing demonstrates mutation agnostic efficacy in pre-clinical retinopathy models. [RNA-seq: RPE65-KO]
2024-06-06 | GSE238216 | GEO
Genomics A combination treatment based on drug repurposing demonstrates mutation agnostic efficacy in pre-clinical retinopathy models.
| PRJNA998379 | ENA
Genomics A combination treatment based on drug repurposing demonstrates mutation-agnostic efficacy in pre-clinical retinopathy models [scRNA-seq: Rd10]
| PRJNA983249 | ENA
Genomics A combination treatment based on drug repurposing demonstrates mutation agnostic efficacy in pre-clinical retinopathy models. [RNA-seq: Rd10]
| PRJNA998385 | ENA
Genomics A combination treatment based on drug repurposing demonstrates mutation-agnostic efficacy in pre-clinical retinopathy models [scRNA-seq: Rpe65-KO]
| PRJNA1099665 | ENA
Genomics A combination treatment based on drug repurposing demonstrates mutation agnostic efficacy in pre-clinical retinopathy models. [RNA-seq: RPE65-KO]
| PRJNA998380 | ENA